Filing Flows

Filing Flows › Companies › Omnicell › Cash flow

Omnicell cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$21.7M in Q3 2026 · $146M over twelve months

Operating cash flow$33.1M
Capital spending−$11.4M
Free cash flow+$21.7M
Cash / net income3.0×
Cash conversion cycle92 days

Analysis

In Q3 2026, Omnicell generated $33.1M of operating cash flow and spent $11.4M on capital projects, leaving free cash flow of $21.7M. That is $3.2M more than in Q3 2025 ($18.5M).

Over the twelve months to Sep 30, 2026, operating cash flow was $186M; the largest uses were capital spending ($40.4M), other financing ($23.0M), other investing ($15.5M); besides operations, cash came from shares issued ($15.7M); the cash balance rose by $112M.

Operating cash flow was $33.1M against net income of $11.0M — 3.0× profit, cash ran ahead of reported earnings. The largest differences: depreciation & amortization +$18.4M, deferred revenue +$15.6M, stock-based pay +$11.4M.

Its cash conversion cycle was 92 days (receivables 69 + inventory 53 − payables 30).

Free cash flow

Omnicell: free cash flow by quarterOmnicell: free cash flow by quarter$47.2MQ4 2024$14.8MQ1 2025$31.0MQ2 2025$18.5MQ3 2025$22.6MQ4 2025$42.1MQ1 2026$59.4MQ2 2026$21.7MQ3 2026
Operating cash flow less capital spending.
Omnicell: operating cash flow against capital spendingOmnicell: operating cash flow against capital spendingOperating cash flowCapital spending$56.3M$9.1MQ4 2024$25.9M$11.2MQ1 2025$42.8M$11.8MQ2 2025$28.3M$9.8MQ3 2025$30.4M$7.7MQ4 2025$54.5M$12.4MQ1 2026$68.3M$8.9MQ2 2026$33.1M$11.4MQ3 2026
Latest (Q3 2026): Operating cash flow $33.1M, Capital spending $11.4M.

Capital allocation, year by year

Omnicell: where the cash came from (up) and went (down), by fiscal yearOmnicell: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow $232MFY2021: Shares issued $67.3MFY2021: Capital spending −$29.0MFY2021: Acquisitions −$354M$299MFY2021FY2022: Operating cash flow $77.8MFY2022: Shares issued $40.2MFY2022: Capital spending −$47.5MFY2022: Acquisitions −$3.4MFY2022: Buybacks −$52.2M$118MFY2022FY2023: Operating cash flow $181MFY2023: Shares issued $23.2MFY2023: Capital spending −$41.5M$204MFY2023FY2024: Operating cash flow $188MFY2024: Net borrowing $166MFY2024: Shares issued $13.4MFY2024: Capital spending −$36.5M$367MFY2024FY2025: Operating cash flow $127MFY2025: Net borrowing −$175MFY2025: Shares issued $16.9MFY2025: Capital spending −$40.4MFY2025: Buybacks −$77.6M$144MFY2025
Over these 5 years operating cash flow totalled $806M; the largest uses were acquisitions ($358M) and capital spending ($195M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$315M
Debtnone
Net cash$315M

Omnicell funds itself: free cash flow was $146M over the last twelve months, with $315M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Omnicell: sources (+) and uses (−) of cash, Q3 2026Omnicell: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$33.1MCash drawn (+) / kept (−)−$14.9MCapital spending−$11.4MOther financing−$7.8MShares issued$6.2MTaxes on employees’ shares−$3.3MOther investing−$1.7MExchange rates−$117K
Omnicell: sources (+) and uses (−) of cash, TTM to Q3 2026Omnicell: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$186MCash drawn (+) / kept (−)−$112MCapital spending−$40.4MOther financing−$23.0MShares issued$15.7MOther investing−$15.5MTaxes on employees’ shares−$9.5MExchange rates−$1.3M

From profit to cash

Omnicell: net income to operating cash flow, Q3 2026Omnicell: net income to operating cash flow, Q3 2026Net income$11.0MDepreciation & amortization$18.4MStock-based pay$11.4MDeferred taxes$2.5MGains on disposals$201KReceivables−$9.0MInventory−$1.6MPayables$11.0MAccrued liabilities$5.0MEmployee-related liabilities$7.5MDeferred revenue$15.6MPrepaid and other assets−$7.5MOther liabilities$638KOperating cash flow$33.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 202669533092
Q2 202669563195
Q1 202668532794
Q4 202568522793
Q3 202571563394
Q2 202576553299
Q1 2025855130106
Q4 2024765128100

Every quarter

QuarterOperating cash flowCapital spendingBuybacksShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$33.1M−$11.4M—$6.2M−$14.9M$21.7M
Q2 2026$68.3M−$8.9M—$97K−$31.8M$59.4M
Q1 2026$54.5M−$12.4M—$7.8M−$39.9M$42.1M
Q4 2025$30.4M−$7.7M—$1.7M−$25.6M$22.6M
Q3 2025$28.3M−$9.8M−$61.9M$6.9M$206M$18.5M
Q2 2025$42.8M−$11.8M——−$17.1M$31.0M
Q1 2025$25.9M−$11.2M—$8.3M−$15.8M$14.8M
Q4 2024$56.3M−$9.1M—$271K$194M$47.2M

Omnicell: income statement and cash flow

Omnicell, Q3 2026: revenue $308M (-0.9% year over year), operating margin 4.9%. The chart follows the revenue to costs, profit and cash.

Omnicell: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.